Ditchcarbon
  • Customers
  1. Organizations
  2. Regeneron
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Regeneron

Company website

Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.

DitchCarbon Score

How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

54

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Regeneron's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.

74%

Let us know if this data was useful to you

Regeneron's reported carbon emissions

In 2024, Regeneron Pharmaceuticals, Inc. reported total greenhouse gas emissions of approximately 1,465,520,000 kg CO2e. This figure includes Scope 1 emissions of about 80,300,000 kg CO2e, Scope 2 emissions of approximately 40,400,000 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled around 1,344,820,000 kg CO2e. The combined Scope 1 and 2 emissions amounted to about 120,700,000 kg CO2e (market-based). For 2023, the company’s total emissions were reported at approximately 972,376,000 kg CO2e, with Scope 1 emissions at about 69,600,000 kg CO2e, Scope 2 emissions (market-based) at approximately 29,900,000 kg CO2e, and Scope 3 emissions reaching around 872,876,000 kg CO2e. Regeneron has set ambitious climate commitments, aiming to reduce its combined Scope 1 and 2 greenhouse gas emissions per square metre by 30% by 2025, using a 2016 peak baseline. This target applies to both Scope 1 and Scope 2 emissions. Furthermore, the company plans to match 100% of its electricity consumption with certified renewable energy sources by 2035, encompassing both Scope 1 and Scope 2 emissions. The emissions data and reduction targets are sourced directly from Regeneron Pharmaceuticals, Inc., with no cascaded data from parent or related organisations.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2018201920202021202220232024
Scope 1
58,200,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
27,800,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
394,571,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Regeneron's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Regeneron is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Regeneron is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Galderma Group AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Allergan

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Boehringer Ingelheim International GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Sarepta Therapeutics

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250825.6
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy